These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Providing antiretroviral therapy for HIV infection. Steinbrook R N Engl J Med; 2001 Mar; 344(11):844-6. PubMed ID: 11248164 [No Abstract] [Full Text] [Related]
4. The cost effectiveness of antiretroviral therapy for HIV disease. Laurence J N Engl J Med; 2001 Jul; 345(1):68; author reply 68-9. PubMed ID: 11439961 [No Abstract] [Full Text] [Related]
5. Efficacy of antiretroviral therapy in resource-poor settings: are outcomes comparable to those in the developed world? Lawn SD; Myer L; Wood R Clin Infect Dis; 2005 Dec; 41(11):1683-4; author reply 1684. PubMed ID: 16267745 [No Abstract] [Full Text] [Related]
6. Sustaining treatment costs: who will pay? Zewdie D; De Cock K; Piot P AIDS; 2007 Jul; 21 Suppl 4():S1-4. PubMed ID: 17620744 [No Abstract] [Full Text] [Related]
7. Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm. Moatti JP; N'Doye I; Hammer SM; Hale P; Kazatchkine M Nat Med; 2003 Dec; 9(12):1449-52. PubMed ID: 14647513 [No Abstract] [Full Text] [Related]
8. First-line antiretroviral therapy in resource-limited settings: time to reconsider? Adlington R; Richens J; Shahmanesh M J Infect Dis; 2009 May; 199(9):1407; author reply 1407-8. PubMed ID: 19358673 [No Abstract] [Full Text] [Related]
9. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations. Pinheiro Edos S; Antunes OA; Fortunak JM Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246 [TBL] [Abstract][Full Text] [Related]
10. Antiretroviral therapy in sub-Saharan Africa: myth or reality? Kebba A J Antimicrob Chemother; 2003 Nov; 52(5):747-9. PubMed ID: 14563895 [No Abstract] [Full Text] [Related]
11. 3 by 5 initiative: treating 3 million by 2005. East Mediterr Health J; 2002 Nov; 8(6):835-7. PubMed ID: 15568463 [No Abstract] [Full Text] [Related]
12. How can earlier entry of patients into antiretroviral programs in low-income countries be promoted? Lawn SD; Wood R Clin Infect Dis; 2006 Feb; 42(3):431-2; author reply 432-3. PubMed ID: 16392093 [No Abstract] [Full Text] [Related]
13. Dual nucleoside therapy in resource-poor and medium-income countries. Colebunders R; Verdonck K Clin Infect Dis; 1999 Sep; 29(3):706-7. PubMed ID: 10530487 [No Abstract] [Full Text] [Related]
14. Commentary: the reality of treating HIV and AIDS in poor countries. Sykes R BMJ; 2002 Jan; 324(7331):216-7. PubMed ID: 11831203 [No Abstract] [Full Text] [Related]
15. HIV resistance and the developing world. Gupta RK; Pillay D Int J Antimicrob Agents; 2007 May; 29(5):510-7. PubMed ID: 17346940 [TBL] [Abstract][Full Text] [Related]
17. [Antiretroviral treatment of HIV infections in poor countries]. Eskesen AN Tidsskr Nor Laegeforen; 2003 Nov; 123(22):3255-7. PubMed ID: 14714026 [No Abstract] [Full Text] [Related]